GDNSF · Goodness Growth Holdings, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $268.77M | $99.38M | $88.13M | $74.63M | $49.21M |
| Cost of Revenue | - | - | - | $39.42M | $31.11M |
| Gross Profit | $127.10M | $50.77M | $44.10M | $30.91M | $17.13M |
| R&D | - | - | - | - | - |
| SG&A | $81.19M | $28.06M | $28.22M | $33.82M | $26.37M |
| Total Operating Expenses | $128.14M | $37.21M | $33.52M | $37.85M | $40.17M |
| D&A | $16.11M | $2.54M | $2.87M | $3.34M | $2.48M |
| Operating Income | ($1.05M) | $13.56M | $10.58M | ($6.94M) | ($23.04M) |
| Interest Expense | - | $31.19M | $31.26M | $22.59M | $5.10M |
| Income Tax | $28.23M | $11.11M | $7.72M | $5.89M | $8.79M |
| Net Income | ($68.11M) | ($28.01M) | ($25.55M) | ($42.46M) | ($22.94M) |
| EPS - Basic | ($0.09) | ($0.16) | ($0.19) | ($0.33) | ($0.24) |
| EPS - Diluted | ($0.09) | ($0.16) | ($0.19) | ($0.33) | ($0.24) |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | $122.49M | $91.60M | $15.96M | $15.15M | $15.16M |
| Accounts Receivable | $12.67M | $2.87M | $3.09M | $4.29M | $4.50M |
| Inventory | $59.97M | $21.67M | $19.29M | $20.51M | $20.42M |
| Accounts Payable | $18.87M | $2.30M | $1.77M | $1.91M | $1.49M |
| Current Assets | $305.11M | $230.37M | $148.85M | $46.73M | $41.64M |
| Total Assets | $817.15M | $278.86M | $183.26M | $159.16M | $166.97M |
| Current Liabilities | $191.53M | $135.47M | $179.47M | $29.71M | $16.41M |
| Long-term Debt | - | - | - | $46.25M | $27.33M |
| Total Liabilities | $509.73M | $223.30M | $199.31M | $155.72M | $123.96M |
| Stockholders' Equity | $307.42M | $55.56M | ($16.04M) | $3.44M | $43.01M |
| Retained Earnings | ($299.55M) | ($231.44M) | ($203.43M) | ($177.88M) | ($135.42M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | $3.71M | ($10.23M) | ($965.9K) | ($18.07M) | ($10.93M) |
| Investing Cash Flow | $8.76M | ($8.13M) | ($3.48M) | ($5.62M) | $12.94M |
| Financing Cash Flow | $18.42M | $94.01M | $5.26M | $23.68M | $15.87M |
| CapEx | $28.32M | $11.69M | $4.96M | $5.56M | $8.45M |
| Free Cash Flow | ($24.61M) | ($21.93M) | ($5.93M) | ($23.63M) | ($19.38M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 47.3% | 51.1% | 50.0% | 41.4% | 34.8% |
| Operating margin | -0.4% | 13.6% | 12.0% | -9.3% | -46.8% |
| EBITDA margin | 5.6% | 16.2% | 15.3% | -4.8% | -41.8% |
| Net margin | -25.3% | -28.2% | -29.0% | -56.9% | -46.6% |
| Free cash flow margin | -9.2% | -22.1% | -6.7% | -31.7% | -39.4% |
| FCF / Net income | 0.36 | 0.78 | 0.23 | 0.56 | 0.84 |
| R&D / Revenue | - | - | - | - | - |
| SG&A / Revenue | 30.2% | 28.2% | 32.0% | 45.3% | 53.6% |
| Effective tax rate | - | - | - | - | - |
| Return on assets | -8.3% | -10.0% | -13.9% | -26.7% | -13.7% |
| Return on equity | -22.2% | -50.4% | 159.2% | -1233.9% | -53.3% |
| Return on invested capital | - | - | - | -11.0% | -25.9% |
| Liquidity | |||||
| Current ratio | 1.59 | 1.70 | 0.83 | 1.57 | 2.54 |
| Quick ratio | 1.28 | 1.54 | 0.72 | 0.88 | 1.29 |
| Cash ratio | 0.64 | 0.68 | 0.09 | 0.51 | 0.92 |
| Leverage | |||||
| Debt / Equity | - | - | - | 13.44 | 0.64 |
| Debt / Assets | - | - | - | 0.29 | 0.16 |
| Debt / EBITDA | - | - | - | - | - |
| Interest coverage | - | 0.4x | 0.3x | -0.3x | -4.5x |
| Equity multiplier | 2.66 | 5.02 | -11.42 | 46.25 | 3.88 |
| Liabilities / Assets | 0.62 | 0.80 | 1.09 | 0.98 | 0.74 |
| Efficiency | |||||
| Asset turnover | 0.33 | 0.36 | 0.48 | 0.47 | 0.29 |
| Inventory turnover | - | - | - | 1.92 | 1.52 |
| Days sales outstanding | 17d | 11d | 13d | 21d | 33d |
| Days inventory outstanding | - | - | - | 190d | 240d |
| Days payable outstanding | - | - | - | 18d | 17d |
| Cash conversion cycle | - | - | - | 193d | 256d |
| Valuation | |||||
| P / E | - | - | - | - | - |
| P / B | 1.5x | 1.8x | - | 6.0x | 3.9x |
| P / S | 1.7x | 1.0x | 0.4x | 0.3x | 3.4x |
| EV / EBITDA | 21.8x | 0.6x | 1.2x | - | - |
| Growth | |||||
| Revenue growth (YoY) | 170.4% | 12.8% | 18.1% | 51.6% | - |
| Revenue CAGR (3y) | 53.3% | 26.4% | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - |
| Gross profit growth (YoY) | 150.3% | 15.1% | 42.7% | 80.5% | - |
| Operating income growth (YoY) | - | 28.2% | - | 69.9% | - |
| Net income growth (YoY) | -143.2% | -9.6% | 39.8% | -85.1% | - |
| EPS growth (YoY) | 43.8% | 15.8% | 42.4% | -37.5% | - |
| EPS CAGR (3y) | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - |
| FCF growth (YoY) | -12.2% | -269.9% | 74.9% | -21.9% | - |
| FCF CAGR (5y) | - | - | - | - | - |
| Book value growth (YoY) | 453.3% | - | - | -92.0% | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$268.77M totalRetail$219.93M · 81.8%
Wholesale Product$48.84M · 18.2%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
0.37
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
3/9
Weak
- ✗Net income positive
- ✓Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- ✗Gross margin improved
- ✗Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Goodness Growth Holdings against the 5 most active filers in the same SIC group.